-

New cardiology guidelines require use of ultrasound enhancing agent during stress echo for perfusion

CHICAGO--(BUSINESS WIRE)--New international cardiology guidelines require the use of an ultrasound enhancing agent during stress echocardiograms to assess myocardial perfusion in patients with ischemia, as well as left ventricular heart function, according to a British cardiologist who is a co-author of the guidelines.

“Not using an ultrasound enhancing agent is akin to depriving patients of the benefit of the test, thereby compromising the management of the patients,” Dr. Roxy Senior said Thursday at the annual Advances in Contrast Ultrasound conference in Chicago. Dr. Senior is a professor of clinical cardiology at the National Heart and Lung Institute of the Imperial College London and a member of the Board of Directors of the International Contrast Ultrasound Society.

According to Dr. Senior, contrast enhanced stress echocardiograms are now considered “Class 1” imaging tests under the newly released 2024 European Society of Cardiology Guidelines for the Management of Acute Coronary Syndromes.

“That means if you don’t use it, you are doing a disservice to patients,” he added.

According to Dr. Senior, studies show that mortality is lowered by effectively evaluating ischemia so that appropriate treatment may be timely implemented.

“Lives are saved when ultrasound enhancing agents are used to look at perfusion as well as heart function,” he said.

Dr. Senior also implored the ultrasound industry to improve their equipment so that ultrasound machines more effectively leverage the benefits of ultrasound enhancing agents.

“Progress has stalled since 2010, but these guidelines create an important opportunity for the vendors while also setting out what is needed for patient care,” he said.

Ultrasound enhancing agents are comprised of suspensions of tiny injectable “microbubbles” that do not contain dye, create no known risk of kidney damage or deposit of contrast media in the brain, and do not expose patients or hospital staff to ionizing radiation.

Ultrasound contrast agents are currently available worldwide from Bracco, Lantheus and GE Healthcare.

ABOUT ICUS:

The International Contrast Ultrasound Society (ICUS) is a nonprofit medical society dedicated to advancing the safe and medically appropriate use of contrast enhanced ultrasound (CEUS) to improve patient care globally. Membership in ICUS is available free of charge and there is no fee for ICUS CME-accredited educational programs, newsletters or other resources.

To join ICUS and learn more about CEUS, download ICUS Connect and visit the ICUS website (www.icus-society.org).

Contacts

International Contrast Ultrasound Society
Linda Maiman Feinstein, Advisor -- 847-624-1844 or 312-876-2563, Linda.Feinstein@Dentons.com
Robin J. Adams, Director of Communication -- 202-408-3946, Robin.Adams@Dentons.com

The International Contrast Ultrasound Society


Release Summary
New international cardiology guidelines require an ultrasound enhancing agent during stress echocardiograms, according to a British cardiologist.
Release Versions

Contacts

International Contrast Ultrasound Society
Linda Maiman Feinstein, Advisor -- 847-624-1844 or 312-876-2563, Linda.Feinstein@Dentons.com
Robin J. Adams, Director of Communication -- 202-408-3946, Robin.Adams@Dentons.com

More News From The International Contrast Ultrasound Society

CMS Doubles Payment for Contrast-Enhanced Ultrasound Scans

CHICAGO--(BUSINESS WIRE)--Payment for certain contrast-enhanced ultrasound (CEUS) imaging procedures will double under a newly assigned billing code, according to an announcement by the International Contrast Ultrasound Society (ICUS) which advocated for the reimbursement upgrade. The change, published in the Federal Register today and effective January 1, 2026, will increase non-cardiac CEUS reimbursement from $170.02 to $358.35. It also reassigns non-cardiac CEUS to the same billing code used...

Contrast Enhanced Ultrasound Shows 100% Sensitivity and Specificity for Finding Residual or Recurrent Kidney Tumors

CHICAGO--(BUSINESS WIRE)--Contrast enhanced ultrasound (CEUS) is superior to contrast magnetic resonance (MR) and computed tomography (CT), and offers 100% sensitivity and specificity, for finding residual or recurrent kidney tumors in patients who have had a kidney-sparing procedure, according to a new study announced today at the 39th annual International Bubble Conference in Chicago. The study assessed 193 kidney lesions in 188 patients at two medical centers over approximately six years, ac...

New Studies Show Microbubble Ultrasound Contrast Agents Improve Liver Tumor Response to Radiotherapy and Survival

CHICAGO--(BUSINESS WIRE)--Two new clinical trials show that microbubble ultrasound contrast agents safely and effectively improve liver tumor responses to radiotherapy and patient survival, according to results announced today by Dr. John Eisenbrey, professor of radiology at Thomas Jefferson University, at the 39th annual International Bubble Conference in Chicago. One study found that patients with aggressive intrahepatic cholangiocarcinoma (ICC) and liver metastasis showed a greater than 50%...
Back to Newsroom